Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?

Amgen (AMGN -1.34%) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo Nordisk (NVO -0.45%) and Eli Lilly (LLY 0.77%). If it succeeds, it'll be showing up to the market late, and it'll need to clear the high bar of proving that its product is worth using instead of the mainstays.Is its stock worth buying on what appears to be its long shot at accessing a market that's already white-ho ...